What is Werewolf Therapeutics Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Werewolf Therapeutics's operating assets for the quarter that ended in Mar. 2024 was $38.41 Mil. Werewolf Therapeutics's operating liabilities for the quarter that ended in Mar. 2024 was $8.74 Mil. Werewolf Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $174.83 Mil. Therefore, Werewolf Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.17.
Werewolf Therapeutics Scaled Net Operating Assets Historical Data
The historical data trend for Werewolf Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics Scaled Net Operating Assets Chart
|
Werewolf Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
-1.80 |
-6.55 |
0.11 |
0.04 |
0.18 |
|
Werewolf Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
0.17 |
0.17 |
0.19 |
0.16 |
0.17 |
Competitive Comparison of Werewolf Therapeutics's Scaled Net Operating Assets
For the Biotechnology subindustry, Werewolf Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's Scaled Net Operating Assets falls into.
Werewolf Therapeutics Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Werewolf Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (40.49 | - | 11.536) | / | 160.245 |
| = | 0.18 |
where
Werewolf Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Mar. 2024 ) |
| = | (Operating Assets (Q: Mar. 2024 ) | - | Operating Liabilities (Q: Mar. 2024 )) | / | Total Assets (Q: Dec. 2023 ) |
| = | (38.411 | - | 8.742) | / | 174.833 |
| = | 0.17 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics (Werewolf Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
Executives
| Ra Capital Healthcare Fund Lp |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Luke Evnin |
director |
THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
| Meeta Chatterjee |
director |
C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
| Michael A. Sherman |
director |
3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
| Chulani Karunatilake |
officer: Chief Technology Officer |
1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138 |
| Reid Leonard |
officer: Chief Operating Officer |
1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138 |
| Mpm Oncology Innovations Fund Lp |
10 percent owner |
450 KENDALL STREET, CAMBRIDGE MA 02142 |
| Longwood Fund Iii Gp, Llc |
10 percent owner |
800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199 |
| Derek Dirocco |
director |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Moshe Arkin |
10 percent owner |
6 HACHOSHLIM ST., HERZELIA L3 4672406 |
| Alon Lazarus |
director, 10 percent owner |
C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
| Daniel J Hicklin |
director, 10 percent owner, officer: See Remarks |
|
| Sphera Funds Management Ltd. |
10 percent owner |
4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
| Sphera Global Healthcare Management Lp |
10 percent owner |
4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
| Sphera Global Healthcare Gp Ltd. |
10 percent owner |
4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
Werewolf Therapeutics (Werewolf Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HOWL has been successfully added to your